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[57] ABSTRACT 
A composition which is a contraceptive with potent 
anti-HIV activity. The composition is a high energy 
coprecipitate of nonoxynol-9 oligomers, polyvinylpyr 
rolidone (PVP) and iodine or PVP-I and shows a pro 
nounced synergistic, anti-HIV effect between the com 
pounds of the composition. A method of obtaining a 
contraceptive and anti-HIV environment in a female 
comprising administering to said female an effective 
amount of a high energy coprecipitate. 
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HIGH ENERGY COPRECIPITATE OF 
NONOXYNOL OLIGOMER, PVP AND IODINE 
HAVING CONTRACEPTIVE AND POTENT 
ANTI-HIV PROPERTIES 
TECHNICAL FIELD 
The present invention relates to a composition which 
is a contraceptive with potent anti-HIV activity. The 
composition is a high energy coprecipitate of nonox 
ynol oligomers, polyvinylpyrrolidone (PVP) and iodine 
and shows a pronounced synergistic effect between the 
compounds of the composition. 
BACKGROUND 
Nonoxynol or nonylphenol(polyethoxy)ethanol is a 
nonionic surfactant used as the active ingredient in the 
majority of the commercially available spermicides. It 
inhibits the in vitro growth of venereal pathogens (see 
Benes, S. et al., (1985) Antimicrob. Agent Chemother. 27: 
724-726; Kelly, J. P. et al., (2985), Antimicrob. Agent 
Chemother 27: 760-762; Austin, H., et al., (2984) JAMA, 
251: 2822-2824; and Singh, B. et al., (1972) Br. J. Vener. 
Dis. 48: 57-64), including the herpes simplex viruses (see 
Asculai, S. S. et al., (1978) Antimicrob. Agent Chemother. 
13: 686-690; Hicks, D. R., (1985) Lancet, 1422-1423; 
Friedman-Kein, (1986) J. Am. Acad. Dermal. 15: 
20 
25 
989-994; RaPP, R- et al., (1985) Antimicrob. Agent’ 
Chemother. 28: 449-451; Voeller, B., (1986) Lancet, 
1153; Malkovsky, M. et al., (1988) Lancet, 645; and 
Barbi, M. et al., (1987) Boll. 1st. Sieroter. (Milan) 66: 
158-160). _ 
By the nature of its synthesis, the nonoxynol-9 (N-9) 
(Igepal CO-630) derivative of nonoxynol is a polymer 
consisting of at least 17 oligomers of varying ethylene 
oxide (EO) chain length. The molecule of N-9 contains 
a hydrophobic moiety (nonylphenol portion) and a 
hydrophilic chain composed basically of ethylene oxide 
units. The compound is a product of a statistical poly 
merization reaction of 9 moles of ethylene oxide and 
one mole of nonylphenol (see equation below): 
0 
where “n” represents the number of ethylene oxide 
units. 
The above reaction does not yield a distinct com 
pound but a mixture of oligomers with different molec 
ular weights. The physical and chemical characteristics 
of these oligomers change as a function of the varying 
molecular weight. (See Liebert, M. A., (1983) J. Am. 
Coll. Toxicol. 2: 35-60). As the length of the E0 chain 
increases, the oligomers increase in water solubility. 
Nonoxynol-9 oligomers 1 through 6 (n=1-6) are con 
sidered oil soluble compounds, whereas the oligomers 
with a longer E0 chain are soluble in water and polar 
organic solvents (see Liebert, supra). 
These differences in chemical properties of N-9 oligo 
mers affect their biological behavior both in vitro and in 
vivo. For instance, it was noted that the dermal toxicity 
45 
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of nonoxynol decreases as the molecular weight in 
creases (see Liebert, supra) and that smaller molecular 
weight nonoxynol may be more toxic to fibroblasts than 
the larger ones (see Chvapil, M. et al., (1980) Fertil. 
Steril. 33: 521-525). 
The in vitro spermicidal activity of the N-9 surfactant 
is also related to its molecular weight. Thus the oligo 
mer n=9 when separated from the N-9 compound, was 
much more effective in inhibiting the motility of the 
spermatozoa than the higher molecular weight nonox 
ynols where n =30, 50, and 100. (See Chvapil, M. et al., 
(1980) Fertil. Steril. 33: 521-525.) The lower molecular 
weight nonoxynols (n=1 or 4) could not be studied 
appropriately because of their poor solubility in the 
aqueous testing medium (see Chvapil, supra). 
Analogous dependence on molecular weight was 
observed in vivo. Oral absorption studies in the rat 
indicated that increasing the length of the ethylene 
oxide chain decreased N-9 oligomer intestinal absorp 
tion (see Knaak, J. B. et al., (1966) Toxicol. Appl. Phar 
macol. 9: 331-340). Furthermore, data showed that 
absorption of N-9 through the vaginal membrane was 
poor and re?ects the preferential absorption of lyophilic 
low molecular weight oligomers. (See Walter, B. A. et 
al. (1988) Toxicol. Applied Pharmacol. 96: 258-268.) 
An efficient high pressure liquid chromatography 
(HPLC) method for the separation of [14C]N-9 and 
characterization of the oligomeric components of the 
spermicide N-9 has been developed. (See Walter, B. A. 
et a1. (1988) Toxicol. Applied Phannacol. 96: 258-268; 
and Walter, B. A. et al., (1991) Phamz. Res. 8: 409-411). 
Utilizing this normal phase gradient elution HPLC 
method, at least seventeen oligomers were isolated from 
commercial N-9. Selected oligomers representing the 
high, medium and low molecular weight fraction of N-9 
were separated in milligram quantities by normal phase 
gradient HPLC (see Waiter, B. A. et al., (1991) Pharm. 
Res. 8: 409-411; and Walter, B. A. et al., (1991) Pharm. 
Res. 8: 403-408). 
Polyvinylpyrrolidone (also known as povidone USP) 
is one of the most highly utilized polymers in medicine 
because of its safety for human use and unique hydro 
philic properties (see Robinson, B. V. et al. (1990), A 
critical review of the Kinetics and Toxicology of Polyvinyl 
pyrrolidone, Lewis Publishers, Inc., Michigan). 
Discovered and used during World War II as a 
plasma expander, PVP is currently used as excipient in 
many pharmaceutical preparations intended for external 
use (e.g. povidone-iodine USP solutions such as Beta 
dine); for oral use, such as a solubilizing agent and tablet 
disintegrant, and fox vaginal use such as in PVP-I 
douche. 
Several studies have focused on the dissolution rate 
behavior of drug-povidone coprecipitates. (See Higu 
chi, W. I. et al., (1983) in Proceedings of the International 
Symposium on Povidione, Digenis, G. A. and Arisell, J ., 
Eds. Lexington, pp. 71-79; Simonelli, A. P. et al., (1987) 
in Proceedings of the 2nd International Symposium on 
Povidone, Digenis, G. A. and Agha, B. J., Eds., Lexing 
ton, pp. 392-401; Simonelli et al., (1969) J. Phamz. Sci, 
58: 538-549; Simonelli et al. (1976) ibid. 65: 355-361.) 
These studies found that the preferential dissolution 
of one component (hydrophilic polymer, such as PVP) 
can enhance the dissolution of the other component in a 
coprecipitate. 
Drug/PVP high energy coprecipitates can be de 
scribed as a drug incorporated into a solid PVP solu 
5,380,523 
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tion. Drug release from PVP coprecipitates are shown 
to follow dissolution kinetics of the polymer carrier of 
PVP provided that the PVP solvent uptake or swelling 
proceeds freely without inhibition by the drug. 
Mayersohn and Gibaldi (Mayersohn M. et al., (1966) 
J. Pharm. Sci. 55: 1323-1324) showed greatly enhanced 
dissolution of the antibiotic griseofulvin when the drug 
was coprecipitated with povidone (PVP). I-Iiguchi et al. 
investigated a povidone/sulfathiazole system and sug 
gested that the resultant enhanced aqueous solubility of 
sulfathiazole was due to a high energy state of the drug 
in the PVP coprecipitate resulting in a supersaturated 
form of the drug after introduction into aqueous media. 
(See Higuchi, W. I. et al., (1983) in Proceedings of the 
International Symposium on Povidz'one, Digenis, G. A. 
and Ansell, J ., Eds. Lexington, pp. 71-79.) 
Simoneill et al., envisioned a PVP/drug coprecipitate 
model consisting of two components including the drug 
in amorphous state and PVP. (Simonelli, A. P. et al., 
(1987) in Proceedings of the 2nd International Symposium 
on Povidone, Digenis, G. A. and Agha, B. J., Eds., Lex 
ington, pp. 392-401; Simonelli et al., (1969) J. Pharm. 
Sci. 58: 538-549; Simonelli et a1. (1976) ibid. 65: 
355-361.) 
The in vitro spermicidal activity of three molecular 
weight fractions of N-9 were compared to that of N-9, 
using rabbit spermatozoa, at equimolar concentrations. 
nonoxynol-9/PVP complexes were found to be far 
more effective in immobilizing the sperm than either 
N-9 alone or in the separate fractions (Walter, B. A. et 
al., (1991) Pharm. Res. 8: 403-408). 
The spermicidal activities of three oligomeric frac 
tions of N-9 with human sperm have been assessed. 
Equimolar concentrations of three different molecular 
weight fractions of N-9 coprecipitated with PVP were 
used. These equimolar concentrations were 166 ug/ml 
for high molecular weight (HMW), (MW=599), 123 
pg/ml for middle molecular weight 
(MMW>(MW=499) and 85 ug/ml for low molecular 
weight (LMW) (MW: 306) N-9 fractions. The order of 
ef?cacy in immobilizing the human spermatozoa was 
HMW(MW =599)> MMW(MW =499)>LMW(MW 
=306) with complete sperm immobilization observed 
with PVP coprecipitated with N-9 HMW within 4.0 
minutes and PVP coprecipitated with N-9 MMW 
within 15 minutes after exposure. Furthermore, addi 
tion of the spermicides interfered with the progressive 
motility and linearity of the sperm swimming pattern. 
PVP and buffer controls showed no decline in percent 
age motility over the course of the test. 
Chvapil et al. recognized that the n=9 oligomeric 
fraction of nonoxynol-9 was more effective in inhibiting 
the motility of spermatozoa than the higher molecular 
weight nonoxynols. Chvapil et al., however, were un 
able to study the lower molecular weight oligomers 
(n=l-4) because of their poor solubility in aqueous 
media. 
In contrast, however, Walter et al. were able to solu 
bilize the water insoluble lower molecular weight N-9 
oligomers by complexing them with the hydrophilic 
polymer polyvinylpyrrolidone (PVP). (See Walter, B. 
A. et al., (1991) Pharm. Res. 8: 403-408.) 
The resulting high energy coprecipitate complexes of 
the low molecular species of N-9 were found to be at 
least effective spermicides at all concentrations tested 
when compared to their counterparts that were pre 
pared from higher molecular weight N-9 oligomeric 
fractions. However, they were themselves effective 
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spermicides. The above ?ndings concluded that when 
N-9 is coprecipitated with PVP its spermicidal activity 
is enhanced. While PVP alone has no inherent sperm 
toxicity, the formation of N-9/PVP complexes seem to 
produce a synergistic response which causes a more 
rapid damage to the sperm than any of the two materials 
alone (Walter, B. A. et al., (1991) Pharm. Res. 8: 
403-408). 
Nonoxynol-9 (N -9) has been shown to be useful in the 
prophylaxis against sexually transmitted diseases 
(STD). (See Bird, K. D., (1991) AIDS 5: 791-796; and 
Louv, W. C. et al., (1988) J. Infect. Dis 158: 518-523). 
More recently, this spermicide has been shown to be 
effective against cell-associated HIV at concentrations 
of 20.05% (v/v). (See Hicks, D. R. et al., (1985) Lan 
cet, ii: 1422-1423; Vopeller, B., (1986) Lancet, i: 1153; 
and Malkovsky, M., Newell, A., Dalgleish, A. G., 
(1988) Lancet, i: 645). 
Unfortunately, N-9 causes epithelial disruption of the 
cervix and vagina when administered in high doses and 
high frequency (see Niruthisard S. et al., (1991) Sex. 
Transm. Dis. 18: 176-179). Higher rates of new HIV 
infections were found in prostitutes who used N-9 at 
great frequencies (see Kreiss, J. et al., International 
Conference on AIDS, Montreal, June 1989 [Abstract 
MAO36]). This observation was attributed to the high 
incidence of genital ulceration caused by high doses of 
N-9, in this group of women. Thus, the above ?ndings 
tend to suggest that novel spermicide formulations con 
taining N-9 should be ef?cacious at the smallest possible 
doses so that the integrity of the vaginal epithelium is 
not compromised. 
The antimicrobia properties of povidone-iodine 
(PVP-I), a complex of polyvinyl pyrrolidone and io 
dine, have been well documented. PVP-I solutions 
(10% w/v) USP are among the most widely utilized 
antimicrobial agents. A 10% (w/v) solution of PVP-I 
contains 1% (w/v) of available iodine (1;). The microbi 
ological potency of PVP-I arises from the elemental 
(diatomic) or free iodine (12) in solution. The signi?cant 
characteristic ‘of iodophores, such as PVP-I, is that they 
carry almost all of their iodine in a complexed form so 
that the amount of free iodine (I2) is quite low and 
PVP-I serves as the iodine reservoir delivering the free 
iodine into the solutions. Thus, iodophors exhibit re 
duced irritation properties and are relatively non-toxic 
(see LaRocca, R. et al., (1983) in Proceedings of the 
International Symposium on Povidone, Digenis, G. A. 
and Ansell, J., Eds. Lexington, pp. 101-119). 
Stable, sterile (0.2%) PVP-I compositions containing 
as little as 0.02% iodine have been shown to be useful in 
treating eye infections in humans. A level of 0.02% 
iodine obtained byrdiluting a commercial 10% PVP-I 
solution at 1:50 with saline solution, is generally consid 
ered to be optimum to maximize performance and mini 
mize irritation (see Winicov, M. et al., (1987) in Proceed 
ings of the International Symposium on Povidone, Dige 
nis, G. A. and Ansell, J., Eds. Lexington, pp. 57-64). 
Data has shown that with doubly labeled 1“'C-PVP 
1311 solutions the amount of iodine delivered into gram 
positive and negative bacteria cultures was three times 
greater when the iodine was complexed with PVP, than 
from an equimolar solution of 131I3-—(Lugol’s solution). 
(See Digenis, G. A. et al., (1983) in Proceedings of Inter 
national Symposium on Povidone, Digenis, G. A. and 
Ansell, J., Eds. Lexington, pp. 302-311). 
The hydrophilic polymer PVP acts as a delivery 
system for iodine probably due to the membrane seek 
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ing properties of this polymer. Ben-David and Gavendo 
have shown that PVP at 4.6% w/v concentrations 
protect red blood cells from osmotic fragility and me 
chanical injury. (See Ben-David A. et al., (1972) Cryobi 
ology, 9: 192-197). These workers suggested that this 
effect is brought about by a “coating” or external inter 
action of PVP with cell membranes. 
The membrane-seeking properties of PVP suggest 
that in addition to its contribution to the solubilization 
ability of N-9, the PVP polymer, via its cell-membrane 
coating properties, also provides vaginal and cervical 
surface coverage coating with N-9 and iodine over 
extended periods of time. 
In addition to its antimicrobial properties, PVP-I has 
been shown to inactivate HIV. (See Kaplan, I. C. et al. 
(1987) Infect. Control 8: 412-424; and Harbison, M. A. et 
al., (1989) J. Acquir. Immune De?c. Syndr. 2: 16-20). 
The concentration of iodine used in Kaplan’s studies 
was equal to 0.025% for 250 ppm of 1;. 
A 0.02% w/v (200 ppm) solution of iodine is consid 
ered non-toxic and non-irritating and is used for treat 
ment of eye infections in humans. (See Winicov, M. et 
al., (1987) in Proceedings of the International Symposium 
on Povidone, Digenis, G. A. and Ansell, J ., Eds. Lexing 
ton, pp. 57-64). In fact, the increased bactericidal activ 
ity of dilute solutions of povidone-iodine (Betadi 
ne—l0% w/v PVP-I) have recently been well docu 
mented. Betadine contains 10,000 ppm (or 10,000 
[lg/ml) of available iodine and is often irritating to the 
tissues and has an undesirable brown color. (See Berkel 
man, R. L. et al., (1982)]. Clin. Microbiol. 15: 635-639.) 
At concentrations of about 0.02% w/v of iodine, the 
undesirable brown color of iodine is not a problem since 
in dilute solutions the color is hardly seen and the 
amount of iodine is not irritating to tissues. 
None of the prior research in this area recognized the 
synergistic anti-HIV result of all three compounds 
when formulated into a high energy coprecipitate. 
Furthermore, spermicides containing nonoxynol-9 
and polyvinylpyrrolidone or polyurethane are known. 
U.S. Pat. No. 4,317,447 to Williams discloses a device 
for delivering a medicament to the vaginal cavity con 
sisting of a molded sheath of a mixture of a polymeric 
material and a medicament. The medicament which is 
dispersed in the polymeric material can be nonoxynol-9. 
The polymer may be selected from modi?ed cellulose, 
polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic 
and ethylene oxide polymer. Williams does not disclose 
the use of PVP-I in combination with a nonoxynol-9. 
U.S. Pat. No. 5,156,164 to LeVeen et al. discloses that 
iodine can be dissolved in alcohol containing nonoxynol 
in a complex with polyurethane. LeVeen et al. disclose 
that a polyvinylpyrrolidone-iodine complex has been 
effective in treating resistant vaginitis. LeVeen et al. do 
not disclose or suggest combining PVP-I with nonox 
ynol. 
U.S. Pat. No. 5,070,889 to Leveen et al. discloses a 
contraceptive sponge and tampon made of polyure 
thane iodine complex. Leveen et al. teaches away from 
the use of povidone iodine or use as a contraceptive. 
U.S. Pat. No. 5,073,365 to Katz et al. discloses clinical 
and personal care articles enhanced by lubricants and 
adjuvants. The devices can be made of polyvinylpyrrol 
idone or polyurethane interpolymers. The device may 
take the form of vaginal diaphragms, tampons, condoms 
or cervical caps. The medicament may be nonoxynol-9. 
Katz et al. disclose that the personal care articles may 
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prevent the transmission of venereal diseases, possibly 
including AIDS. 
U.S. Pat. No. 4,707,362 to Nuwayser discloses a sus 
tained release composition made of synthetic polymers 
such as polyvinylpyrrolidone. The bioerodible material 
in one embodiment has been modi?ed so that a spermi 
cide such as nonoxynol-9 is slowly released. Nuwayser 
does not disclose PVP-I in combination with nonox 
ynol-9. 
U.S. Pat. No. 4,954,351 to Sackler et al. discloses a 
method of producing standardized povidone-iodine 
preparations. The patent discloses that the povidone-io 
dine solution can be incorporated into a suppository 
with 0.1 to 10% by Weight of povidone-iodine. Sacklet 
et al. do not disclose the use of povidone-iodine in com 
bination with nonoxynol-9. 
U.S. Pat. No. 4,297,341 to Waller et al. discloses that 
a water-soluble complex comprising polyvinylpyrroli 
done and gossypol is an effective spermicide. The pa 
tent discloses that a PVP-gossypol combination when 
compared to a comparative example of nonoxynol-9 
alone, exhibited equal or greater spermicidal properties. 
Waller does not disclose PVP-I in combination with 
nonoxynol-9. 
U.S. Pat. No. 4,925,033 to Stoner et al. discloses a 
microbicidal cleanser/barrier kit. One method of the 
invention involves applying a solution of povidone-io 
dine (PVP-I) to vaginal sponges or condoms. In another 
embodiment the povidone-iodine active ingredient may 
be added to spermicidal birth control compounds. 
Stoner et al. disclose that nonoxynol-9 is a known sper 
micidal compound. Stoner et al. do not disclose or sug 
gest the particular combination of components in the 
form of a high energy coprecipitate, nor that the com 
pounds show a synergistic anti-HIV effect. 
Heterosexual transmission of human immunode? 
ciency virus (HIV), the causative agent of AIDS, is a 
growing concern in the United States where 37% of 
AIDS cases are heterosexually transmitted, the major 
ity being male-to-female. Moreover, the frequency of 
global heterosexual transmission is probably greater 
where it is estimated to exceed 60% of all AIDS cases. 
It has been suggested that a major contributing factor 
to heterosexual transmission of HIV is the presence of 
cell-free virus and virus-infected cell (cell-associated 
virus in genital secretions. Thus, vaginal contraceptives 
which inactivate HIV should be an effective barrier to 
transmission. 
There is a need in the pharmaceutical area for a a 
contraceptive with potent anti-HIV activity. Ideally, a 
contraceptive agent is needed that can: 
la) provide rapid spermicide delivery (within 30-60 
seconds); 
lb) provide long-actingsperrnicidal activity after a 
single application; 
2) protect the user against HIV (AIDS) and other 
sexually transmitted diseases (STDs); 
3) protect vaginal and cervical epithelia from irrita 
tron; 
4) enhance penetration of spermicide into cervical 
mucus; 
5) exhibit low systemic bioavailability (low absorp 
tion); 
6) be pharmaceutically and cosmetically acceptable 
(e.g. a tablet or capsule are preferred, as supposito 
ries, creams and gels appear not to be as attractive 
to young users). 
5,380,523 
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The composition of the invention meets the above 
objectives and provides a high energy coprecipitate of 
nonoxyno1-9 oligomers, polyvinylpyrrolidone and io 
dine (PVP-I). The composition shows a pronounced 
synergistic effect between the compounds which results 
in potent anti-HIV activity. The composition of the 
invention safely and cost-effectively provides a contra 
ceptive with potent anti-HIV activity. 
Disclosure of the Invention 
It is an object of the invention to provide a novel and 
potent contraceptive and/or spermicide possessing pro 
nounced anti-HIV properties which is a high energy 
coprecipitate composition comprising N-9 oligomers 
and PVP and iodine. The PVP and iodine ingredients 
may be present in the coprecipitate composition as the 
complex PVP-I. 
The invention further provides a high energy copre 
cipitate composition which is in the form of a powder. 
In a preferred embodiment the invention provides a 
high energy coprecipitate composition including PVP-I 
which comprises about 0.09-9% W/w of iodine. 
In yet another embodiment, the invention provides a 
high energy coprecipitate composition of N-9 com 
plexed with PVP‘ comprising an antiviral concentration 
of free iodine of about 0.03% w/v or about 300 ppm. 
The invention additionally provides a high energy 
coprecipitate composition of N-9 complexed with PVP 
comprising an antiviral concentration of free iodine 
providing about 9.4 to 0.09 % I2 providing an effective 
concentration of free iodine of 0.0094% w/v (94 ppm) 
and from about ‘11.8 —5.8% w/w of N-9 providing an 
effective concentration of N-9 of 0.0058% w/v (58 
ppm) 
In a further embodiment, the invention includes a 
high energy coprecipitate composition comprising an 
effective ?nal concentration of from about 4-200 pg/ml 
of N-9. 
The invention advantageously provides for a method 
of preparing a high-energy coprecipitate composition 
comprising the steps of: 
(a) fractionating commercially available spermicide 
N-9 to seventeen oligomers by a preparative high 
pressure liquid chromatography (HPLC) proce 
dure; and 
(b) converting the oligomers or commercially avail 
able N-9 to a high energy coprecipitate with PVP 
and iodine. 
Preferred is a method of preparing a high-energy 
coprecipitate composition including the steps of: 
(a) fractionating commercially available spermicide 
nonoxynol-9 (N-9) to seventeen oligomers by high 
pressure liquid chromatography (HPLC); 
(b) adding an N-9 oligomer obtained in step (a) with 
a 10% or 1% solution w/v of PVP-I in a solvent, 
(c) placing the product of step (b) in an oil bath at 
about 100° C., and allowing the solvent to evapo~ 
rate. 
(d) obtaining a high energy coprecipitate of N-9, 
polyvinylpyrrolidone (PVP) and iodine. 
Also included is a method of treating a female com 
prising administering to a female an effective amount of 
a high energy coprecipitate comprising N-9 oligomers, 
PVP and iodine to achieve a contraceptive and anti 
HIV environment in the vaginal cavity. Thus, the in 
vention provides spermicidal and anti-HIV activity 
with no irritation to the cervical and vaginal epithelia, 
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and may take the form of an elegant, free ?owing pow 
der. 
DESCRIPTION OF THE INVENTION 
The present invention describes methodology for the 
preparation and assessment of new chemical entities 
with pronounced spermicidal and anti-HIV properties. 
These chemical entities incorporate N-9 or selected N-9 
oligomers, small amounts of iodine (l2) and the hydro 
philic polymer PVP in such a way as to form high 
energy complexes, also known as coprecipitates. 
The novel contraceptive composition of the inven 
tion comprises a high energy coprecipitate made from 
N-9 oligomers, PVP and iodine. A pronounced syner 
gistic effect is obtained between the compounds, en 
hancing the anti-HIV activity of the compounds when 
in the form of a coprecipitate. Due to the synergistic 
effect of the compounds present in the high energy 
coprecipitate, the coprecipitate requires less of each of 
the individual ingredients to achieve the desired anti 
HIV result, than if the compounds were to be adminis 
tered as a mixture. This is bene?cial as it reduces irrita 
tion to tissues caused by higher doses of N9 and iodine 
and thus reduces the potential for HIV virus transmis 
sion. 
The high energy coprecipitates of the invention are 
formulated by fractionating commercially available 
spermicide, N-9, into seventeen oligomers by a prepara 
tive high pressure liquid chromatography (HPLC) pro 
cedure. Selected oligomers of N-9, or the commercially 
available N-9, are converted to high energy coprecipi 
tates with PVP and various amounts of iodine (PVP-I). 
In a preferred embodiment the amount of iodine is 
about 0.09-9% w/w of iodine. The content of N-9 in 
the above complexes, in a preferred embodiment, 
ranges from 5.8-12% w/w. 
N-9 and its oligomeric components are inherently 
viscous liquids which are converted to free ?owing, 
water soluble powders by forming coprecipitates with 
PVP-I. Several combinations of iodine (I2), N-9 and 
PVP are utilized to produce powders which exhibit a 
variety of spermicidal and anti-HIV activities. 
In order to test and compare the anti-HIV activity of 
the high energy coprecipitates of the invention, the 
following assay procedure was performed. 
Procedure for Anti-HIV Activity Assessment 
High-titer suspensions (>106infectious particles/ml) 
were incubated with each compound for 5 seconds, 
then immediately diluted 1:50 onto cultures of human 
MT-2 cells for detection of infectivity. Cellular toxicit 
ies were observed and no antiviral activities were ex 
pected after the 1:50 dilution, hence all antiviral activity 
would have resulted from the 5 second exposure. Infec 
tions were monitored by syncytium (giant cells) forma 
tion and Immune Fluorescence Assay (IFA). This assay 
utilizes all antiviral antibody with a ?uorochrome at 
tached to it through a covalent bond. Virus particles get 
to ?uoresce when viable, and therefore the degree of 
infectivity is quantitated. 
The results after 3, 5 and 8 days of incubation are 
shown in Table 1. In the control experiment, using the 
untreated virus, the MT-2 cells are 100% infected at the 
end of 3 days. 
A 1% value or less, indicates a complete inactivation 
of the virus as measured by the IFA method, i.e. no 
?uorescent particles of the virus exist inside or outside 
the cells (Table l). 
5,380,523 
Syncytia (giant cell) formation is assessed by staining 
techniques with subsequent microscopic examination. 
Syncytia formation indicates invasion of the MT-2 cells 
by the virus. 
The method described is that of Montefiori et al. 
“Evaluation of Antiviral Drugs and neutralizing anti 
bodies to human immunode?ciency virus by a rapid and 
sensitive microtiter infection assay”, J. Clin. lllicrobiol. 
1988, Vol 26: 231-235, incorporated herein by refer 
ence. 
Table 1 summarizes the results of anti-HIV activity 
assessment of two high energy coprecipitate powders of 
PVP-I and N-9. The ?rst was made with oligomers of 
N-9 with an average molecular weight of 599 and the 
second with the oligomers of N-9 with an average mo 
lecular weight of 306. Both samples were coprecipi 
tated with PVP, iodine and one of N-9 oligomers men 
tioned above. 
TABLE 1 
Inactivation of Cell-Free and‘ Cell-Associated HIV-11 
3 days 5 days 
Syncytia IFAZ Syncytia 
+++ >80% cm;3 
8 days 
IFA 
CPE 
DRUG 
PVP 
(11.8 mg/ml) 
PVP 
(0.236 mg/ml) 
PVP 
(3.24 mg/ml) 
high MW N-9 
(0.2 mg/ml) 
PVP 
(0.0648 mg/ ml) 
high MW N-9 
(0.004 tug/ml) 
PVP 
(5.8 mg/ ml) 
10W NW N-9 
(0.2 mg/ ml) 
PVP 
(0.116 mg/ml) 
low MW N-9 
(0.004 mg/ml) 
PVP-I 
(11.8 mg/ml) 
PVP-I 
(0.236 mg/ml) 
PVP-I 
(3.24 mg/ml) 
high MW N-9 
(—) 
(0.2 mg/ml) 
PVP-I 
(0.0648 mg/ml) 
high MW N-9 
(0.004 mg/ml) 
PVP-I 
(5.8 mg/ ml) 
low MW N-9 
(0.2 mg/ ml) 
PVP-I 
(0.116 mg/ml) 
low MW N-9 
(0.004 mg/ ml) 
+ + + 
1Details of experimental procedures are given in the test. 
1% IFA positive cells 
3CPE, viral-induced cytopathic effect was complete. 
HMW N-9 = 599 
LMW N-9 = 306 
IFA 
CPE 
+ + + > 80% CPE CPE CPE 
- 10% + + + > 80% CPE 
+ + + > 80% CPE CPE CPE 
10% + + + > 80% CPE 
+ + + > 80% CPE CPE CPE 
+ + + > 30% CPE CPE CPE 
+++ <1% <l% 0% 
+ + + > 80% CPE CPE CPE 
CPE 
0% 
CPE CPE +++ 
- <1% 
> 80% CPE CPE CPE 
The data in Table 1 show that PVP-I at a concentra 
tion of 11.8 mg/ml completely inactivated cell-free and 
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cell-associated HIV-1. This represents approximately 
an effective concentration of 1.2% w/v of PVP-I or 
0.12% w/v of free iodine (or 1,200 ppm of 12). 
A solution was made from a PVP—I and N-9 high 
energy coprecipitate. The coprecipitate composition 
was 94.2% w/w of PVP-I and 5.8% W/w of N-9, at a 
concentration of 3.24 mg/ml of PVP-I and 0.2 mg/ml of 
N-9 of an average molecular weight of 599. This com 
position achieved a complete eradication of the HIV 
virus in 30 seconds. 
The use of high molecular weight N-9 oligomers as a 
component of the anti-HIV coprecipitate composition 
decreases the systemic absorption of N-9 and therefore 
N-9 is localized in the vagina and less toxic to the fe 
male. 
Similar anti-HIV results were obtained with a copre 
cipitate of about 5.8 mg/ml PVP-I and about 0.2 mg/ml 
N-9 of an average molecular weight of 306. These re 
sults represent an antiviral concentration of free iodine 
of about 0.03% w/v (324 ppm). This level of iodine is 
not irritating to the vaginal epithelial tissue and desir 
ably has no noticeable brown color. 
In contrast to the above results, when no iodine is 
present in a coprecipitate composition made with 94.2% 
w/w of PVP and 5.8% w/w of N-9, at a concentration 
of 3.24 mg/mL of PVP and 0.2 mg/mL of N-9 of an 
average molecular weight of 599, the antiviral proper 
ties of the product were substantially reduced (see 
Table 1). 
A similar reduction of the antiviral properties was 
also observed when the product was made from a 
PVP/N-9 high energy coprecipitate of 94.2% w/w of 
PVP and 5.8% w/w of N-9, at a concentration of 3.24 
mg/mL of PVP and 0.2 mg/mL of N-9 of an average 
molecular weight of 599 (see Table 1). 
Thus, in a preferred embodiment, the presence of 324 
ppm iodine in the case of high molecular weight (599) 
N-9. and 580 ppm of iodine, in the case of the lower 
molecular weight N-9 (306) importantly adds to the 
synergistic anti-HIV effect of the high energy coprecip 
itate. The iodine and N-9 both act in a synergistic man 
ner when complexed with PVP. 
Other solutions made from PVP-I and N-9 coprecipi 
tate in accordance with the invention include 94.2% of 
PVP-I and 5.8% of N-9 with an average molecular 
weight of 599. A further solution made from PVP-I and 
N-9 coprecipitate comprises 94.2% of PVP and 5.8% of 
N-9 with a weight average molecular weight of 306. 
The chemical union of the iodine, PVP and several 
oligomers of the spermicidal agent N-9 with different 
molecular weights results in an impressive synergistic 
action of iodine and the spermicide N-9 against human 
immunode?ciency virus (HIV) (Tables 1 and 2). 
The coprecipitate of the invention shows that the 
synergism between iodine and N-9 is of such magnitude 
that solutions with even smaller concentrations of these 
species can be used. Again, this is bene?cial as it reduces 
vaginal irritation and thus reduces the potential for HIV 
virus transmission. Indeed, a complete eradication of 
the HIV-virus was obtained when coprecipitates of 
PVP, iodine and N-9 solution, containing as low as 58 
ppm of N-9 and 940 ppm of PVP-I (94 ppm of iodine), 
were utilized (see Table 2). 
TABLE 2 
Concentration on Virus 
IgglmL = ppm| Syncytia IFA Position 
5,380,523 
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TABLE 2-continued 
Compound N9 PVP-I % Cells % 
No drug — — 100 100 
KYO48 58 940 0 0 
101050 117.4 10 10 s 
KY052 118 0 30 10 
compggition of KY Coprecipitates 
PVP PVP-I 12 N-9 
% ppm % ppm % ppm % ppm 
KY048 0 0 94.20 940,000 9.40 94,000 5.80 58,000 
KYOSO 88.58 885,800 0.90 9,400 0.09 940 10.52 105,200 
KY052 88.20 882,000 0 0 0 0 11.8 118,000 
15 The following examples are given to illustrate the 
The synergistic effect against the HIV is so signi? 
cant that the above PVP-I/N-9 solution at concentra 
tions as small as 58 ppm of N-9 and 94 ppm of iodine are 
effective, against the HIV virus (Table 2). 
In addition to the unexpected synergism between the 
compounds, the coprecipitation of iodine, N-9 and PVP 
results in the formation of freely ?owing powders 
which enable the preparation of elegant solid pharma 
ceutical formulations with control release properties. 
The coprecipitate powders are particularly useful in the 
design of acceptable solid formulations intended for 
vaginal, or other appropriate use. 
The coprecipitate composition may be administered 
in the form of solid formulations, such as tablets or 
capsules, or as ointments, creams or suppositories. In a 
preferred embodiment the composition is administered 
in the form of a capsule or tablet. 
Tablets, capsules, ointments, creams or suppositories 
may be formulated according methods known in the art 
such as those disclosed in Remington’s Pharmaceutical 
Science, 18th Ed. pp. 1602-1712, incorporated herein by 
reference. 
In contrast, N-9 by itself is a viscous liquid which 
cannot be formulated as a powder in solid dosage forms 
such as tablets or capsules. N-9 has heretofore been 
unable to form elegant tablets or capsules which are 
preferred by the user cover creams and suppositories. 
Additionally, at its generally accepted effective spermi 
cidal concentrations (approximately 160 mg/ml), N-9 is 
irritating to the vaginal epithelia and lining of the vagi 
nal vault. 
At concentrations below 550 ppm neither iodine nor 
N-9 are known to irritate sensitive membrane linings of 
the human body. Thus, the coprecipitate powders can 
be formulated into drug delivery systems that can re 
lease their active ingredients in a predictable manner 
without causing irritation to surrounding membrane 
linings. 
The powders of the invention are acceptable to the 
user and furnish prolonged protection against AIDS 
and sexually transmitted diseases (STDs) with minimal 
absorption to the systemic circulation. 
The main ingredient in the powders of the high en 
ergy coprecipitates, described in this invention, is the 
hydrophilic polymer PVP. This polymer, which exists 
in the powders in a ratio of approximately forty parts to 
one part of N-9, not only enhances the solubility of the 
various N-9 oligomers but also contributes to the syner 
gistic action of N-9 and iodine against the AIDS virus. 
Thus, in a most important aspect of the invention, the 
active ingredients (N-9 and iodine) are present in the 
powder in such minuscule quantities that are known not 
to irritate membrane linings of the body. 
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invention, but are not to be construed as limiting. 
EXAMPLE 1 
The various compositions of coprecipitates are made 
according to the following general procedure: Stock 
solutions of approximately 1% w/v of PVP-I and 1% 
w/v N-9 are made in ethanol or methanol. 
The N-9 stock solution is added dropwise to an ali 
quot of the PVP-I stock solution with stirring. It is 
critical that the two solutions are mixed at a very slow 
rate. Thus, the introduction of the N-9 solution, into the 
round bottom ?ask, containing the PVP-I, must be done 
dropwise but over a period of not longer than 1.5 hours. 
Subsequently, the solvent is evaporated from the 
PVP-I/N-9 solution by heating in a preheated oil bath 
at 100° C. The temperature must be kept constant at 
100° C. The evaporation process should last between 
l-2 hours but no longer than two hours. 
EXAMPLE 2 
If a “glassy” coprecipitate is obtained following the 
general procedure described in example 1, diethyl ether 
is mixed with the residue. Upon evaporation of the 
diethyl ether a crystalline powder is obtained. 
EXAMPLE 3 
If a ?nely divided crystalline powder of the PVP 
I/N-9 coprecipitate is desired, following the procedure 
described in Example 1, the residue, received after 
evaporation described in Example 1, is dissolved in a 
mixture of methanol/ 1,4 dioxane (1:4 ratio v/v) and 
subjected to freeze-drying for at least 12 hours. A fine 
crystalline powder is obtained by the freeze-drying step. 
EXAMPLE 4 
Commercially available nonoxynol-9 containing sev 
enteen oligomers with an average molecular weight of 
599 is utilized as a component in the general procedure 
described in Example 1. The oligomer of N-9 is isolated 
by the HPLC procedure disclosed in Walter, B. A. et a1. 
(1988) T oxicol. Applied Pharmacol. 96: 258-268; Walter, 
B. A. et al., (1991) Pharm. Res. 8: 409-411; and Walter, 
B. A. et al., (1991) Pharm. Res. 8: 403-408, incorporated 
herein by reference). 
Brie?y, the separation is achieved by a preparative 
Zorbax-NHZ column (250 mm, 7 pm, ><2l.l mm i.d.). 
EXAMPLE 5 
Stock solutions of N-9 (250 mg/ml) were prepared in 
tetrahydrofuran. A 1.0 ml aliquot was separated on a 
preparative Zorbax-NH2 7 pm column, 250 mm><2l.2 
mm I.D., using a linear solvent gradient from 98% 
A-2% B to 50% A—50% B in 90 min., where A=tet 
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rahydrofuranzhexane (20:80, v/v) and B=water:2 
propanol (10:90, v/v) delivered at 9.9 ml/min at ambi 
ent temperature and detection at 280 nm. The HPLC 
system used was a Waters HPLC system (Millipore, 
Waters Chromatography Division, Millford, Mass.) 
consisting of two Waters Model 510 HPLC pumps, a 
Waters Model 680 gradient controller, a Waters Model 
440 Absorbance detector (280 nm), and a Waters Model 
SE120 dual channel recorder. Samples were introduced 
via a Rheodyne Model 7125 loop injector equipped 
with a 100 pl loop onto the HPLC column. Seventeen 
oligomers were collected, concentrated and reinjected 
onto the analytical system for further puri?cation. The 
599 molecular weight fraction and 305 molecular 
weight fraction were separated from the other fractions. 
A 10% or 1% solution of w/v of PVP-I and the MW 
599 fraction of the compound of nonoxynol-9 (N9) 
(isolated as set forth above) in absolute ethanol (metha 
nol) was made. Both solutions were added via dropping 
funnels into a round bottom ?ask. It is important in this 
step to allow the dropping of the two solutions to con 
tinue for 1.5 hours. Thus the addition of the two solu 
tions must take place slowly. 
To an oil bath which had been preheated to 100° C., 
the ?ask was placed and the solvent allowed to evapo 
rate. It was important to make sure that the temperature 
was well controlled during the evaporation process. 
The evaporation process should take between 1 and 2 
hours. The evaporation should not take place longer 
than 2 hours. 
A high energy coprecipitate of the compounds is 
obtained. 
Examples 6-8 .show formulations of the high energy 
coprecipitate of the invention. 
EXAMPLE 6 
A high energy coprecipitate composition of 
9.4-0.09% I w/w and ll.8-5.8% N-9 w/w. The high 
energy coprecipitate provides anti-HIV protection at an 
effective concentration of about 3.24 mg/mi of PVP-I 
and 0.2 mg/ml of N-9 of an average molecular weight 
of 599 in a tablet formulation. 
EXAMPLE 7 
A high energy coprecipitate providing anti-HIV pro 
tection at an effective concentration of about 5.8 mg/ml 
PVP-I and 0.2 mg/ml N-9 of an average molecular 
weight of 305 in a capsule formulation. 
EXAMPLE 8 
A high energy coprecipitate providing anti-HIV pro 
tection at an effective concentration of about 58 ppm of 
N-9 and 940 ppm of PVP-I or 94 ppm of iodine in a 
cream formulation. 
The invention is not to be limited to the exact details 
of operation, or to the exact compositions, methods, 
procedures or embodiments shown and described, as 
obvious modi?cations and equivalents will be apparent 
to one skilled in the art. The invention is therefore to be 
limited only by the full scope which can be legally 
accorded to the appended claims. 
We claim: 
1. A composition comprising a high energy coprecip 
itate of nonoxynol oligomer and polyvinylpyrrolidone 
polymer and iodine, or polyvinylpyrrolidone-iodine 
complex (PVP-I), wherein the combined effect of the 
compounds simultaneously precipitated in said high 
energy coprecipitate exceeds the individual effect of 
said compounds, and wherein said high energy copre 
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cipitate has antiviral activity against human im 
munode?ciency virus-l (HIV-1) in an MT-2 assay. 
2. A composition according to claim 1, wherein said 
coprecipitate is a powder. 
3. A composition according to claim 2, wherein said 
powder is a ?nely divided crystalline powder. 
4. A composition according to claim 1, wherein said 
PVP-I comprises about 0.09—9.4% w/w of iodine. 
5. A composition according to claim 1, wherein said 
PVP-I comprises an antiviral concentration of free io 
dine of about 0.03% w/v or 300 ppm complexed with 
PVP. 
6. A composition according to claim 1, wherein said 
PVP-I comprises an effective antiviral concentration of 
free iodine of about 0.0094 w/v of iodine or 94 ppm 
complexed with PVP. 
7. A composition according to claim 1, wherein said 
nonoxynol oligomer of said coprecipitate comprises 
from about 5.8 to 11.8% W/w of nonoxynol-9 oligomer. 
8. A composition according to claim 1, wherein said 
coprecipitate is present at a concentration of about 3.24 
mg/ml of PVP-I and about 0.2 mg/ml of N-9 oligomer 
of an average molecular weight of 599. 
9. A composition according to claim 1, wherein said 
coprecipitate is present at a concentration of about 5.8 
mg/ml PVP-I and about 0.2 mg/ml N-9 oligomer of an 
average molecular weight of 306. 
10. A composition according to claim 1 wherein said 
coprecipitate is present at a concentration of about 5.8 
ppm of N-9 oligomer and about 940 ppm of PVP-I or 94 
ppm of iodine. 
11. A composition of claim 1, wherein said nonoxynol 
oligomer is an nonoxynol-9 oligomer with an average 
molecular weight of 599. ‘ 
12. A composition of claim 1, wherein said nonoxynol 
oligomer is nonoxynol-9 oligomer comprising oligo 
mers of N-9 having a range of molecular weight of each 
oligomer from about 264 to about 1000. 
13. A composition of claim 1, wherein the percent of 
polyvinylpyrrolidone ranges from about 88% to about 
97%. 
14. A composition of claim 1, wherein the average 
molecular weight of said polyvinylpyrrolidone ranges 
from about 2,500 to 1,100,000. 
15. A method of preparing a composition according 
to claim 1, comprising the steps of: 
(a) fractionating commercially available spermicide 
nonoxynol-9 (N-9) to seventeen oligomers by high 
pressure liquid chromatography (HPLC); 
(b) adding an N-9 oligomer obtained in step (a) with 
a 10% or 1% solution w/v of PVP-I in a solvent, 
(c) placing the product of step (b) in an oil bath at 
about 100° C., and allowing the solvent to evapo 
rate; and 
(d) obtaining a high energy coprecipitate of N-9, 
polyvinylpyrrolidone (PVP) and iodine. 
16. A method of achieving a contraceptive and anti 
HIV in environment the vaginal cavity of a female 
comprising administering to said vaginal cavity of said 
female an effective amount of a composition according 
to claim 1 to achieve a contraceptive and anti-HIV in 
environment the vaginal cavity of said female. 
17. The method according to claim 16, wherein said 
coprecipitate is administered in a form selected from the 
group consisting of tablets, capsules, ointments, creams 
and suppositories. 
18. The method according to claim 16, wherein said 
effective amount of said coprecipitate comprises from 
about 6-12% w/v N-9 and about 0.09—9% w/v of PVP 
I. 
* 1: * * i 
